ProstaCaid™ inhibits tumor growth in a xenograftmodel of human prostate cancer

Jiahua Jiang, Jagadish Loganathan, Isaac Eliaz, Colin Terry, George Sandusky, Daniel Sliva

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

We have recently demonstrated that the dietary supplement ProstaCaid™ (PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro. In the present study, we evaluated toxicity and whether PC suppresses growth of prostate cancer in a xenograft model of human prostate cancer cells implanted in mice. Here, we show that an oral administration of PC (100, 200 and 400 mg/kg) did not affect body weight or activity of liver enzymes (ALT, AST) and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. In addition, PC treatment resulted in the inhibition of tumor volumes (1024.6±378.6 vs. 749.3±234.3, P<0.001) in a xenograft model of prostate cancer with human hormone refractory (independent) PC-3 prostate cancer cells. Moreover, qRT-PCR analysis demonstrated significant upregulation of expression of CDKN1A (p21) and inhibition of expression of IGF2, NR2F2 and PLAU (uPA) genes by an oral administration of PC in prostate cancer xenografts. Our study demonstrates that the concentrations of the dietary supplement ProstaCaid tested did not show signs of toxicity, and its oral application has significant anticancer activity in vivo and can be considered as an alternative treatment for prostate cancer patients.

Original languageEnglish
Pages (from-to)1339-1344
Number of pages6
JournalInternational Journal of Oncology
Volume40
Issue number5
DOIs
StatePublished - May 2012

Fingerprint

Prostatic Neoplasms
Growth
Neoplasms
Heterografts
Dietary Supplements
Oral Administration
ProstaCaid
Liver
Tumor Burden
Up-Regulation
Spleen
Body Weight
Hormones
Kidney
Polymerase Chain Reaction
Lung
Enzymes
Therapeutics
Genes

Keywords

  • Dietary supplement
  • Prostate cancer
  • Xenograft

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

ProstaCaid™ inhibits tumor growth in a xenograftmodel of human prostate cancer. / Jiang, Jiahua; Loganathan, Jagadish; Eliaz, Isaac; Terry, Colin; Sandusky, George; Sliva, Daniel.

In: International Journal of Oncology, Vol. 40, No. 5, 05.2012, p. 1339-1344.

Research output: Contribution to journalArticle

Jiang, Jiahua ; Loganathan, Jagadish ; Eliaz, Isaac ; Terry, Colin ; Sandusky, George ; Sliva, Daniel. / ProstaCaid™ inhibits tumor growth in a xenograftmodel of human prostate cancer. In: International Journal of Oncology. 2012 ; Vol. 40, No. 5. pp. 1339-1344.
@article{0612e479eb414badb4f67a0695074eaa,
title = "ProstaCaid™ inhibits tumor growth in a xenograftmodel of human prostate cancer",
abstract = "We have recently demonstrated that the dietary supplement ProstaCaid™ (PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro. In the present study, we evaluated toxicity and whether PC suppresses growth of prostate cancer in a xenograft model of human prostate cancer cells implanted in mice. Here, we show that an oral administration of PC (100, 200 and 400 mg/kg) did not affect body weight or activity of liver enzymes (ALT, AST) and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. In addition, PC treatment resulted in the inhibition of tumor volumes (1024.6±378.6 vs. 749.3±234.3, P<0.001) in a xenograft model of prostate cancer with human hormone refractory (independent) PC-3 prostate cancer cells. Moreover, qRT-PCR analysis demonstrated significant upregulation of expression of CDKN1A (p21) and inhibition of expression of IGF2, NR2F2 and PLAU (uPA) genes by an oral administration of PC in prostate cancer xenografts. Our study demonstrates that the concentrations of the dietary supplement ProstaCaid tested did not show signs of toxicity, and its oral application has significant anticancer activity in vivo and can be considered as an alternative treatment for prostate cancer patients.",
keywords = "Dietary supplement, Prostate cancer, Xenograft",
author = "Jiahua Jiang and Jagadish Loganathan and Isaac Eliaz and Colin Terry and George Sandusky and Daniel Sliva",
year = "2012",
month = "5",
doi = "10.3892/ijo.2012.1344",
language = "English",
volume = "40",
pages = "1339--1344",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - ProstaCaid™ inhibits tumor growth in a xenograftmodel of human prostate cancer

AU - Jiang, Jiahua

AU - Loganathan, Jagadish

AU - Eliaz, Isaac

AU - Terry, Colin

AU - Sandusky, George

AU - Sliva, Daniel

PY - 2012/5

Y1 - 2012/5

N2 - We have recently demonstrated that the dietary supplement ProstaCaid™ (PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro. In the present study, we evaluated toxicity and whether PC suppresses growth of prostate cancer in a xenograft model of human prostate cancer cells implanted in mice. Here, we show that an oral administration of PC (100, 200 and 400 mg/kg) did not affect body weight or activity of liver enzymes (ALT, AST) and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. In addition, PC treatment resulted in the inhibition of tumor volumes (1024.6±378.6 vs. 749.3±234.3, P<0.001) in a xenograft model of prostate cancer with human hormone refractory (independent) PC-3 prostate cancer cells. Moreover, qRT-PCR analysis demonstrated significant upregulation of expression of CDKN1A (p21) and inhibition of expression of IGF2, NR2F2 and PLAU (uPA) genes by an oral administration of PC in prostate cancer xenografts. Our study demonstrates that the concentrations of the dietary supplement ProstaCaid tested did not show signs of toxicity, and its oral application has significant anticancer activity in vivo and can be considered as an alternative treatment for prostate cancer patients.

AB - We have recently demonstrated that the dietary supplement ProstaCaid™ (PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro. In the present study, we evaluated toxicity and whether PC suppresses growth of prostate cancer in a xenograft model of human prostate cancer cells implanted in mice. Here, we show that an oral administration of PC (100, 200 and 400 mg/kg) did not affect body weight or activity of liver enzymes (ALT, AST) and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. In addition, PC treatment resulted in the inhibition of tumor volumes (1024.6±378.6 vs. 749.3±234.3, P<0.001) in a xenograft model of prostate cancer with human hormone refractory (independent) PC-3 prostate cancer cells. Moreover, qRT-PCR analysis demonstrated significant upregulation of expression of CDKN1A (p21) and inhibition of expression of IGF2, NR2F2 and PLAU (uPA) genes by an oral administration of PC in prostate cancer xenografts. Our study demonstrates that the concentrations of the dietary supplement ProstaCaid tested did not show signs of toxicity, and its oral application has significant anticancer activity in vivo and can be considered as an alternative treatment for prostate cancer patients.

KW - Dietary supplement

KW - Prostate cancer

KW - Xenograft

UR - http://www.scopus.com/inward/record.url?scp=84860277903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860277903&partnerID=8YFLogxK

U2 - 10.3892/ijo.2012.1344

DO - 10.3892/ijo.2012.1344

M3 - Article

C2 - 22293856

AN - SCOPUS:84860277903

VL - 40

SP - 1339

EP - 1344

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 5

ER -